Spots Global Cancer Trial Database for diffuse large b cell lymphoma (dlbcl)
Every month we try and update this database with for diffuse large b cell lymphoma (dlbcl) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| A Study of NX-1607 in Adults With Advanced Malignancies | NCT05107674 | Ovarian Cancer,... Gastric Cancer GastroEsophagea... Head and Neck S... Metastatic or U... Non-small Cell ... Metastatic Cast... Malignant Pleur... Triple Negative... Metastatic Urot... Cervical Cancer Diffuse Large B... Richter Transfo... Microsatellite ... | NX-1607 Paclitaxel | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | NCT04824794 | Relapsed or Ref... Diffuse Large B... Acute Myeloid L... | GEN3014 Daratumumab | 18 Years - | Genmab | |
| Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) | NCT06050694 | Diffuse Large B... | glofitamab | 18 Years - | University Health Network, Toronto | |
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Bio-CAR-T BS Study | NCT05366569 | Diffuse Large B... Primary Mediast... Acute Lymphobla... | 18 Years - 70 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | NCT02362997 | Hodgkin Lymphom... Diffuse Large B... Peripheral T-Ce... | Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | NCT05234684 | Diffuse Large B... | Orelabrutinib +... Placebo + R-CHO... | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma | NCT04113226 | Chemotherapy Diffuse Large B... Elderly | Rituximab Lenalidomide 20... Comprehensive G... Activities of d... | 75 Years - | Centre Hospitalier Universitaire, Amiens | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
